177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

Inclusion Criteria: * Giving a written informed consent * Histopathologically confirmed high or very high risk prostate cancer * Completion of radical locoregional treatment * Completion of locoregional treatment within 3 months before inclusion to the study * ECOG performance status 0 to 2 * Age over 18 years * Within 28 days before entering the study, there were no signs of cancer dissemination documented in radiological tests * Castrate testosterone level (testosteron \< 50 ng/dL lub 1,7 nmol/L) * Patients with adequate function of main organs: * bone marrow: * neutrophils \> 1500x10\^9/L; * thrombocytes \> 100,000x10\^9/L; * hemoglobin \> 9 g/dL * liver: * bilirubin \< 2xULN (upper limit of normal) in patients with Gilbert's syndrome \< 5xULN; * aminotransferase \< 3xULN * kidneys: * eGFR \> 50 ml/min * albumin \>2.5 mg/ml * For men of reproductive age: the need to use double barrier contraception Exclusion Criteria: * The presence of distant metastases confirmed by radiological examination * Absence of approval to use effective contraception method * Absence of Patient's consent to participate in the Study * Urinary tract obstruction or/and hydronephrosis. * Concurrent anticancer treatment.